Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Position Boosted by Golden State Equity Partners

Golden State Equity Partners increased its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 1,390.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 19,380 shares of the company’s stock after purchasing an additional 18,080 shares during the quarter. Golden State Equity Partners’ holdings in Mirum Pharmaceuticals were worth $801,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 10.9% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,179 shares of the company’s stock valued at $421,000 after purchasing an additional 1,003 shares during the last quarter. R Squared Ltd acquired a new stake in Mirum Pharmaceuticals during the 4th quarter worth about $69,000. Secure Asset Management LLC lifted its stake in Mirum Pharmaceuticals by 9.3% during the fourth quarter. Secure Asset Management LLC now owns 39,920 shares of the company’s stock valued at $1,651,000 after buying an additional 3,406 shares in the last quarter. Avanza Fonder AB acquired a new position in shares of Mirum Pharmaceuticals in the fourth quarter worth about $189,000. Finally, Hennion & Walsh Asset Management Inc. increased its position in shares of Mirum Pharmaceuticals by 25.5% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock worth $6,021,000 after acquiring an additional 29,545 shares in the last quarter.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the transaction, the chief executive officer now directly owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Joanne Quan sold 6,969 shares of the business’s stock in a transaction dated Friday, January 17th. The stock was sold at an average price of $45.86, for a total value of $319,598.34. Following the completion of the sale, the insider now directly owns 5,649 shares of the company’s stock, valued at $259,063.14. This represents a 55.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 30,622 shares of company stock valued at $1,398,791. Insiders own 22.87% of the company’s stock.

Analyst Ratings Changes

MIRM has been the subject of a number of recent analyst reports. Leerink Partners raised their price objective on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Citigroup raised their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a research report on Wednesday, November 13th. Robert W. Baird upped their price target on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright restated a “buy” rating and set a $66.00 price objective on shares of Mirum Pharmaceuticals in a research report on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $57.10.

Mirum Pharmaceuticals Stock Up 0.9 %

MIRM opened at $48.88 on Monday. The company has a market capitalization of $2.35 billion, a PE ratio of -24.20 and a beta of 0.98. The business has a 50-day moving average of $44.31 and a 200-day moving average of $41.92. Mirum Pharmaceuticals, Inc. has a fifty-two week low of $23.14 and a fifty-two week high of $50.00. The company has a debt-to-equity ratio of 1.33, a current ratio of 3.34 and a quick ratio of 3.15.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm had revenue of $90.38 million for the quarter, compared to analyst estimates of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s revenue for the quarter was up 89.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.57) earnings per share. Equities research analysts forecast that Mirum Pharmaceuticals, Inc. will post -1.44 EPS for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.